EC Number | Application | Comment | Organism |
---|---|---|---|
3.1.1.4 | medicine | potential of PLA2 as a biomarker in screening neuroinflammatory disorders in both clinical and research settings | Homo sapiens |
EC Number | Cloned (Comment) | Organism |
---|---|---|
3.1.1.4 | - |
Mus musculus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.1.1.4 | 1-palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine | competitive inhibitor toward sPLA2, dose-dependent inhibition | Homo sapiens | |
3.1.1.4 | 1-palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine | competitive inhibitor toward recombinant sPLA2, dose-dependent inhibition | Mus musculus | |
3.1.1.4 | additional information | is not inhibited by bromoenol lactone or AACOCF3 (arachidonyl trifluoromethyl ketone) | Homo sapiens | |
3.1.1.4 | additional information | recombinant sPLA2 is not inhibited by bromoenol lactone or AACOCF3 (arachidonyl trifluoromethyl ketone) | Mus musculus |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
3.1.1.4 | Ca2+ | is required for catalytic activity. With increase in the concentration of calcium, increase of recombinant PLA2 activity | Homo sapiens | |
3.1.1.4 | Ca2+ | is required for catalytic activity. With increase in the concentration of calcium, increase of recombinant sPLA2 activity | Mus musculus |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.1.1.4 | Homo sapiens | - |
- |
- |
3.1.1.4 | Mus musculus | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.1.1.4 | cerebrospinal fluid | - |
Homo sapiens | - |
3.1.1.4 | serum | sPLA2 activity relative to protein concentration is 2.5fold higher in serum than in lumbar cerebrospinal fluid | Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.1.1.4 | 1,2-bis-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine + H2O | - |
Mus musculus | ? | - |
? | |
3.1.1.4 | 1,2-bis-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine + H2O | - |
Homo sapiens | ? | - |
? | |
3.1.1.4 | 1,2-dioleoyl-L-alpha-phosphatidylcholine + H2O | - |
Mus musculus | ? | - |
? | |
3.1.1.4 | 1,2-dioleoyl-L-alpha-phosphatidylcholine + H2O | - |
Homo sapiens | ? | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.1.1.4 | secretory Ca2+-dependent PLA2 | - |
Mus musculus |
3.1.1.4 | secretory Ca2+-dependent PLA2 | - |
Homo sapiens |
3.1.1.4 | sPLA2 | - |
Mus musculus |
3.1.1.4 | sPLA2 | - |
Homo sapiens |
EC Number | General Information | Comment | Organism |
---|---|---|---|
3.1.1.4 | physiological function | sPLA2 activity is present in lumbar cerebrospinal fluid from healthy individuals 20-77 years old that does not depend on either sex or age. Cerebrospinal fluid sPLA2 activity is increased in patients with Alzheimer disease | Homo sapiens |